Behandling af diabetes mellitus med biologiske laegemidler.

Claus Morten Larsen; Thomas Mandrup-Poulsen

Behandling af diabetes mellitus med biologiske laegemidler.

Translated title of the contribution: Treatment of diabetes mellitus with biologic therapeutics

Claus Morten Larsen, Thomas Mandrup-Poulsen

Research output: Contribution to journal › Journal article › Research › peer-review

1 Citation (Scopus)

Abstract

Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps of the pathogenesis of type 1 and type 2 diabetes which are targeted by biologic therapeutics and reviews the treatment results.
Udgivelsesdato: 2008-Jun-9

Translated title of the contribution	Treatment of diabetes mellitus with biologic therapeutics
Original language	Danish
Journal	Ugeskrift for læger
Volume	170
Issue number	24
Pages (from-to)	2134-7
Number of pages	3
ISSN	0041-5782
Publication status	Published - 2008

Bibliographical note

Keywords: Antibodies, Monoclonal; Antigens, CD3; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Immunologic Factors; Tumor Necrosis Factor-alpha

Cite this

@article{ce623d70acd111ddb538000ea68e967b,

title = "Behandling af diabetes mellitus med biologiske laegemidler.",

abstract = "Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps of the pathogenesis of type 1 and type 2 diabetes which are targeted by biologic therapeutics and reviews the treatment results. Udgivelsesdato: 2008-Jun-9",

author = "Larsen, {Claus Morten} and Thomas Mandrup-Poulsen",

note = "Keywords: Antibodies, Monoclonal; Antigens, CD3; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Immunologic Factors; Tumor Necrosis Factor-alpha",

year = "2008",

language = "Dansk",

volume = "170",

pages = "2134--7",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - Behandling af diabetes mellitus med biologiske laegemidler.

AU - Larsen, Claus Morten

AU - Mandrup-Poulsen, Thomas

N1 - Keywords: Antibodies, Monoclonal; Antigens, CD3; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Immunologic Factors; Tumor Necrosis Factor-alpha

PY - 2008

Y1 - 2008

N2 - Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps of the pathogenesis of type 1 and type 2 diabetes which are targeted by biologic therapeutics and reviews the treatment results. Udgivelsesdato: 2008-Jun-9

AB - Biologic therapeutics are currently not approved for the treatment of patients with type 1 and type 2 diabetes. However, promising results from recent randomized controlled studies suggest that biologic therapeutics have therapeutic potential. This article summarizes the causal steps of the pathogenesis of type 1 and type 2 diabetes which are targeted by biologic therapeutics and reviews the treatment results. Udgivelsesdato: 2008-Jun-9

M3 - Tidsskriftartikel

C2 - 18565296

SN - 0041-5782

VL - 170

SP - 2134

EP - 2137

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 24

ER -